An observational study in Breast Cancer and Exercise and Recovery, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational
Among 100 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — 62 open to participants now, 70 under way, 18 of them phase 3. Breast Neoplasms · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.
Among the 100 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, this one is the 27th largest by planned enrollment of the 29 observational ones, is one of 14 that started in 2026, is one of 29 observational ones, reaches primary completion later than 35 of the 69 other live ones, and was the 96th registered.
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's planned enrollment of 40 is below the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →62 of the 100 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University are open now, in 1 country. Each count lists the studies.
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →100 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 14 started in 2026.
Median enrollment 170 across the 71 interventional studies, 220 across the 29 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 483 studies on the registry; 283 are open to participants now.
12 of the studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT05862610Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC | 2026-12-30 |
| NCT07504367Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityLarge Language Models Assist in Tumor MDT | 2026-12-31 |
| NCT06024187Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Randomized Controlled Trial | 2026-12-31 |
| NCT06121557Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPhase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | 2026-12-31 |
Among the 100 studies in Breast Neoplasms by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, from their registry updates:
The goal of this observational study is to develop and evaluate a large language model (LLM)-based decision support system for exercise prescription in breast cancer patients, aiming to provide personalized decision-making support for postoperative breast cancer rehabilitation.
The main questions it aims to answer are:
How accurate, personalized, and safe are the exercise prescriptions generated by the fine-tuned LLM? How does the model's performance compare with other mainstream or non-fine-tuned models across different stages and subtypes of breast cancer? Participants are postoperative breast cancer rehabilitation patients treated at Sun Yat-sen Memorial Hospital of Sun Yat-sen University. They will have demographic, tumor, treatment, and physical fitness data collected; receive personalized exercise prescriptions automatically generated by the LLM-based system; and provide subjective evaluations on the feasibility and executability of the prescriptions.
Patients with breast cancer who have completed primary surgery and entered the postoperative rehabilitation stage at Sun Yat-sen Memorial Hospital, Sun Yat-sen University (Guangzhou, China).All participants receive individualized exercise prescriptions generated by large language models under physician supervision and approval, and their feedback on the feasibility of these prescriptions is collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Postoperative breast cancer patients at Sun Yat-sen Memorial Hospital will have clinical and physical data collected. Each patient receives an exercise prescription generated by a fine-tuned large language model (LLM)-based decision support system and provides feedback on its feasibility.
Overall Quality Score of Exercise Prescriptions Based on a Five-Dimensional Expert Evaluation Framework
Each exercise prescription will be independently evaluated by six multidisciplinary experts across five dimensions: scientific rationale, personalization, comprehensiveness, safety, and feasibility. Each dimension will be rated on a 5-point Likert scale from 1 to 5. The five dimension scores will be summed to generate an overall quality score ranging from 5 to 25, with higher scores indicating better overall prescription quality. For each prescription, the mean overall score across the six experts will be used for analysis.
Time frame: From enrollment to completion of prescription evaluation at 1 week
Subgroup-Specific Scientific Rationale and Safety Scores of Model-Generated Exercise Prescriptions
Model performance will be evaluated across predefined subgroups based on age, breast cancer stage, molecular subtype, surgical procedure, and treatment modality. Scientific rationale and safety will each be rated on a 1-5 Likert scale, with higher scores indicating better performance. Differences across models and subgroups will be assessed using two-way ANOVA or generalized linear models, including interaction terms between model type and patient characteristics.
Time frame: From enrollment to completion of prescription evaluation at 1 week
Start is estimated for Sep 2026; primary completion for Jul 2027, 9 months later.
Of 1,191 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 9 months is below that.
Counting every sponsor, half of 1,380 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University →